Nephrol Dial Transplant (2000) 15: 1617-1623
© 2000 European Renal Association-European Dialysis and Transplant Association
ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus
1 Department of Internal Medicine, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, and 2 Department of Internal Medicine, Ajou University College of Medicine, Suwon, Korea
Background. ACE polymorphism, especially genotype DD or D allele, may be involved in the progression of diabetic nephropathy. It may also have different effects on the reduction of proteinuria by ACE inhibitors in patients with proteinuria. We investigated the relationship between ACE gene polymorphism and antiproteinuric effect of ACE inhibitors (Benazepril 10 mg/day or Perindopril 4 mg/day) in 83 NIDDM patients with overt proteinuria (urinary protein excretion over 500 mg/day).
Methods. We recruited NIDDM patients with overt proteinuria from our renal clinic. Before entry, previously used ACE inhibitors were withdrawn for at least 2 weeks and baseline proteinuria and albuminuria were measured. Patients were classified into three groups in accordance with ACE genotypes (17 DD; 33 ID; 33 II) and prospectively followed up for 3 months. Various clinical parameters including age, DM duration, body mass index (BMI), 24-h urine sodium, protein and albumin, BUN, serum creatinine, creatinine clearance (Ccr), mean arterial pressure (MAP), and HbA1c were measured in the pre- and post-treatment periods. ACE genotypes were determined by polymerase chain reaction.
Results. There were no significant differences in the clinical parameters such as age, DM duration, BMI, BUN, serum creatinine, Ccr, MAP, HbA1c, and daily urinary excretion of sodium, protein and albumin among three groups (P>0.05). After the 3-month treatment period using ACE inhibitors, there were no significant differences in the reduction of MAP and Ccr among the three groups (P>0.05). However, the percentage reductions in urinary excretion of protein and albumin for DD genotype were significantly higher than in ID and II genotypes (50.9±19.2% vs 19.2±16.0%, 20.2±20.4%; 52.6±23.6% vs 13.5±51.8%, 24.8±23.9%, P<0.05). There were no statistically significant correlations between the levels of baseline proteinuria and albuminuria and the magnitudes of the reduction of proteinuria and albuminuria under ACE inhibition (P>0.05).
Conclusions. Our results suggest that the ACE gene polymorphism might have a role in determining the responsiveness to the antiproteinuric effect of ACE inhibition in proteinuric NIDDM patients.
Keywords: ACE gene; ACE inhibitors; antiproteinuric effect; NIDDM
Correspondence and offprint requests to: Sung-Kyu Ha MD, Department of Internal Medicine, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul Young Dong, PO Box 1217, Seoul, Korea.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Nikzamir, A. Esteghamati, M. Feghhi, M. Nakhjavani, A. Rashidi, and Javad Zavar Reza The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 109 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1511 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nikzamir, M. Nakhjavani, A. Esteghamati, and A. Rashidi Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1274 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Lely, F. G.H. van der Kleij, T. J. Kistemaker, A. J. Apperloo, P. E. de Jong, D. de Zeeuw, and G. Navis Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Costacou, Y. Chang, R. E. Ferrell, and T. J. Orchard Identifying Genetic Susceptibilities to Diabetes-related Complications among Individuals at Low Risk of Complications: An Application of Tree-Structured Survival Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 862 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Narita, S Goto, N Saito, J Song, K Omori, D Kondo, M Sakatsume, and F Gejyo Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism J. Med. Genet., December 1, 2003; 40(12): e130 - 130. [Full Text]
|
|
|
|
 |
|
 S. B. Harrap, C. Tzourio, F. Cambien, O. Poirier, S. Raoux, J. Chalmers, N. Chapman, S. Colman, S. Leguennec, S. MacMahon, et al. The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition Hypertension, September 1, 2003; 42(3): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bluher, G. Lubben, and R. Paschke Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes Diabetes Care, March 1, 2003; 26(3): 825 - 831. [Abstract] [Full Text] [PDF]
|
|